NO814012L - PROCEDURE FOR PREPARING IMIDAZO (4,5-B) -PYRIDINES AND PYRIMIDINES - Google Patents
PROCEDURE FOR PREPARING IMIDAZO (4,5-B) -PYRIDINES AND PYRIMIDINESInfo
- Publication number
- NO814012L NO814012L NO814012A NO814012A NO814012L NO 814012 L NO814012 L NO 814012L NO 814012 A NO814012 A NO 814012A NO 814012 A NO814012 A NO 814012A NO 814012 L NO814012 L NO 814012L
- Authority
- NO
- Norway
- Prior art keywords
- carbon atoms
- group
- imidazo
- phenyl
- optionally
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
I britisk patent 1 445 824 og de europeiske offentlig-gjørelsesskrifter 0.022.495 og 0.024.290 beskrives bl.a. en fremgangsmåte for fremstilling av imidazo[4,5-b]pyridin- og In British patent 1 445 824 and the European publication documents 0.022.495 and 0.024.290, e.g. a method for the preparation of imidazo[4,5-b]pyridine- and
-pyrimidin-derivater med den generelle formel-pyrimidine derivatives of the general formula
hvor where
betyr en alkyl-, alkoksy-, alkylmerkapto- eller alkylsulfinylgruppe med hver 1-4 karbonatomer eller et halogenatom, means an alkyl, alkoxy, alkylmercapto or alkylsulfinyl group each having 1-4 carbon atoms or a halogen atom,
1*2 betyr en alkylsulf inylgruppe med 1-4 karbonatomer eller en alkoksygruppe med 2 eller 3 karbonatomer, som i endestilling er substituert med en alkylsulfinylgruppe med 1-4 karbonatomer, en aralkylsulfinylgruppe med 7-9 karbonatomer, en eventuelt med alkylgrupper med 1-3 karbonatomer, alkoksygrupper med 1-3 karbonatomer og/eller halogenatomer mono-, 1*2 means an alkylsulfinyl group with 1-4 carbon atoms or an alkoxy group with 2 or 3 carbon atoms, which is substituted in the terminal position with an alkylsulfinyl group with 1-4 carbon atoms, an aralkylsulfinyl group with 7-9 carbon atoms, an optionally with alkyl groups with 1- 3 carbon atoms, alkoxy groups with 1-3 carbon atoms and/or halogen atoms mono-,
di- eller trisubstituert fenylsulfinylgruppe eller en eventuelt med alkylgrupper med 1-3 karbonatomer, alkoksygrupper med 1-3 karbonatomer og/eller halogenatomer mono- eller di-substituert nitrofenylsulfinylgruppe, og di- or tri-substituted phenylsulfinyl group or a mono- or di-substituted nitrophenylsulfinyl group optionally with alkyl groups with 1-3 carbon atoms, alkoxy groups with 1-3 carbon atoms and/or halogen atoms, and
X betyr en CH-gruppe eller et nitrogenatom,X means a CH group or a nitrogen atom,
av deres lH-tautomerer og av deres fysiologisk forlikelige salter med uorganiske eller organiske syrer, hvilken fremgangsmåte kjennetegnes ved at en tilsvarende merkaptoforbindelse oksyderes med hydrogenperoksyd eller en persyre. Den således oppnådde sulfinylforbindelse inneholder en liten mengde av uomsatt merkaptoforbindelse og en liten mengde av den tilsvarende sulfonylforbindelse, og disse forurensninger nødvendiggjør en omhyggelig rensning for fremstilling av et produkt med farma-søytisk kvalitet. of their 1H-tautomers and of their physiologically compatible salts with inorganic or organic acids, which method is characterized by a corresponding mercapto compound being oxidized with hydrogen peroxide or a peracid. The sulfinyl compound thus obtained contains a small amount of unreacted mercapto compound and a small amount of the corresponding sulfonyl compound, and these impurities necessitate a careful purification to produce a product of pharmaceutical quality.
Videre er det fra håndbøker i organisk kjemi (C. Ferri, Reaktionen der Organischen Synthese, Verlag: G. Thieme (1978); Kharasch and Meyers: The Chemistry of Organic Sulfur Compounds, vol. 1, 157-159 (1961)), Pergamon Press N.Y.; S. Oae: Organic Chemistry of Sulfur 385-387 (1977), Plenum Press N.Y. og London) kjent, at brom ved oksydasjon av en merkaptoforbindelse til det tilsvarende sulfoksyd representerer et uegnet oksydasjonsmiddel da det forårsaker uønskede bireaksjoner, f.eks. spaltning av karbon-svovel-bindingen, dannelse av karbon-broar-bindinger og/ eller bromering av aromater. Furthermore, it is from handbooks in organic chemistry (C. Ferri, Reaktionen der Organischen Synthese, Verlag: G. Thieme (1978); Kharasch and Meyers: The Chemistry of Organic Sulfur Compounds, vol. 1, 157-159 (1961)), Pergamon Press N.Y.; S. Oae: Organic Chemistry of Sulfur 385-387 (1977), Plenum Press N.Y. and London) known, that bromine when oxidizing a mercapto compound to the corresponding sulfoxide represents an unsuitable oxidizing agent as it causes unwanted side reactions, e.g. cleavage of the carbon-sulfur bond, formation of carbon-bridge bonds and/or bromination of aromatics.
Det er nu overraskende funnet at man kan fremstille forbindelsene med den generelle formel I med bedre renhet og i ut-merkede utbytter også ved oksydasjon av en forbindelse med den generelle formel It has now surprisingly been found that the compounds of the general formula I can be prepared with better purity and in excellent yields also by oxidation of a compound of the general formula
hvor where
X og R^er som innledningsvis angitt, ogX and R^ are as indicated at the outset, and
R3 betyr en alkylmerkaptogruppe med 1-4 karbonatomer eller en alkoksygruppe med 2 eller 3 karbonatomer, som i endestilling er substituert med en alkylmerkaptogruppe med 1-4 karbonatomer, en aralkylmerkaptogruppe med 7-9 karbonatomer, en eventuelt med alkylgrupper med 1-3 karbonatomer, alkoksygrupper med 1-3 karbonatomer og/eller halogenatomer mono-, di- eller tri-substituert fenylmerkaptogruppe eller en eventuelt med alkylgrupper med 1-3 karbonatomer, alkoksygrupper med 1-3 karbonatomer og/eller halogenatomer mono- eller di-substituert nitrofenylmerkaptogruppe, R3 means an alkyl mercapto group with 1-4 carbon atoms or an alkoxy group with 2 or 3 carbon atoms, which is substituted in the end position with an alkyl mercapto group with 1-4 carbon atoms, an aralkyl mercapto group with 7-9 carbon atoms, one optionally with alkyl groups with 1-3 carbon atoms, alkoxy groups with 1-3 carbon atoms and/or halogen atoms mono-, di- or tri-substituted phenyl mercapto group or an optionally with alkyl groups with 1-3 carbon atoms, alkoxy groups with 1-3 carbon atoms and/or halogen atoms mono- or di-substituted nitrophenyl mercapto group,
med brom eller addisjonsforbindelser derav.with bromine or addition compounds thereof.
Oksydasjonen foretas fortrinnsvis i et oppløsningsmiddel, f.eks. i et vandig oppløsningsmiddel så som maursyre, eddiksyre, trifluoreddiksyre, metansulfonsyre, saltsyre eller svovelsyre, eller i et vannfritt oppløsningsmiddel, f.eks. iseddik, metylen-klorid, kloroform, dioksan, tetrahydrofuran, maursyreetylester, eddiksyreetylester, dimetylformamid, dimetylsulfoksyd eller heksametyl-fosforsyretriamid, ved temperaturer mellom -10 og 80°C, fortrinnsvis ved temperaturer mellom 15 og 30°C, i et pH-område fra 0 til 10. Særlig fordelaktig foretas omsetningen i et pH-område fra 3 til 8, hensiktsmessig også i nærvær av en buffer, f.eks. i nærvær av et karboksylat-anion, f.eks. alkali-aceHjat så som natriumacetat, i nærvær av et fosfat så som dinatrium-hydrogenfosfat eller natrium-dihydrogenfosfat, eller i nærvær av et karbonat så som natrium-hydrogenkarbonat eller dinatriumkarbonat, med brom eller med et hypobromitt, f.eks. natriumhypobromitt. The oxidation is preferably carried out in a solvent, e.g. in an aqueous solvent such as formic acid, acetic acid, trifluoroacetic acid, methanesulfonic acid, hydrochloric acid or sulfuric acid, or in an anhydrous solvent, e.g. glacial acetic acid, methylene chloride, chloroform, dioxane, tetrahydrofuran, formic acid ethyl ester, acetic acid ethyl ester, dimethylformamide, dimethyl sulfoxide or hexamethyl phosphoric acid triamide, at temperatures between -10 and 80°C, preferably at temperatures between 15 and 30°C, in a pH range from 0 to 10. The reaction is particularly advantageously carried out in a pH range from 3 to 8, suitably also in the presence of a buffer, e.g. in the presence of a carboxylate anion, e.g. alkali acetate such as sodium acetate, in the presence of a phosphate such as disodium hydrogen phosphate or sodium dihydrogen phosphate, or in the presence of a carbonate such as sodium hydrogen carbonate or disodium carbonate, with bromine or with a hypobromite, e.g. sodium hypobromite.
Forbindelsene fremstilt ved fremgangsmåten ifølge oppfinnelsen kan derefter eventuelt overføres til sine syreaddisjons-salter med uorganiske eller organiske fysiologisk forlikelige syrer. Egnede syrer er for eksempel funnet å være saltsyre, bromhydrogensyre, svovelsyre, melkesyre, citronsyre, vinsyre, maleinsyre eller fumarsyre. The compounds produced by the method according to the invention can then optionally be transferred to their acid addition salts with inorganic or organic physiologically compatible acids. Suitable acids have been found to be, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, lactic acid, citric acid, tartaric acid, maleic acid or fumaric acid.
Utgangsmaterialene som anvendes ved fremgangsmåten, er for de flestes vedkommende kjent fra litteraturen resp. kan fremstilles analogt med fremgangsmåten beskrevet i britisk patent 1 4 45 82 4, nemlig ved ringslutning av et tilsvarende 5,6-diamino-pyrimidin resp. 2,3-diamino-pyridin. The starting materials used in the method are, for the most part, known from the literature or can be prepared analogously to the method described in British patent 1 4 45 82 4, namely by cyclization of a corresponding 5,6-diamino-pyrimidine resp. 2,3-diamino-pyridine.
De følgende eksempler skal illustrere oppfinnelsen ytterligere: Sammenligningseksempel I The following examples will further illustrate the invention: Comparative example I
2- (2-metoksy-4-met<y>lsulfin<y>l-fen<yi>)-lH-imidazo[4,5-b]pyridin2-(2-Methoxy-4-meth<y>lsulfin<y>l-phen<yi>)-1H-imidazo[4,5-b]pyridine
6,6 g 2-(2-metoksy-4-metylmerkapt6-fenyl)-lH-imidazo[4,5-b]-pyridin oppløses i 100 ml kloroform, og ved -15 til -20°C tilsettes dråpevis i løpet av 5 timer en oppløsning av 2,96 g 3- klor-peroksybenzoesyre i 600 ml kloroform. Derefter utristes med en fortynnet sodaoppløsning, kloroform-fasen tørres og inndampes. Residuet renses over en silikagelkolonne (elueringsmiddel: kloroform/metanol = 9:1). Ved tilsetning av eterisk saltsyre til en metanolisk oppløsning av basen får man det gule hydroklorid. 6.6 g of 2-(2-methoxy-4-methylmercapt6-phenyl)-1H-imidazo[4,5-b]-pyridine is dissolved in 100 ml of chloroform, and at -15 to -20°C is added dropwise over 5 hours a solution of 2.96 g of 3-chloro-peroxybenzoic acid in 600 ml of chloroform. It is then shaken out with a dilute soda solution, the chloroform phase is dried and evaporated. The residue is purified over a silica gel column (eluent: chloroform/methanol = 9:1). By adding ethereal hydrochloric acid to a methanolic solution of the base, the yellow hydrochloride is obtained.
Utbytte: 2,3 g (33,6% av det teoretiske),Yield: 2.3 g (33.6% of the theoretical),
smeltepunkt for basen: 154-155°C.melting point of the base: 154-155°C.
Sammenligningseksempel II Comparative example II
2-(2-metoksy-4-metylsulfinyl-fenyl)-1H-imidazo[4,5-b]pyridin-hydroklorid 2-(2-Methoxy-4-methylsulfinyl-phenyl)-1H-imidazo[4,5-b]pyridine hydrochloride
En oppløsning av 135,6 g (0,5 mol) 2-(2-metoksy-4-metyl-merkapto-fenyl)-1H-imidazo[4,5-b]pyridin i 600 ml 80%ig eddiksyre tilsettes 57 g 30%ig hydrogenperoksyd og får stå i 2 dager ved--laboratorietemperatur. Efter tilsetning av ytterligere 5 g 30%ig hydrogenperoksyd lar man reaksjonsblandingen stå ved laboratorietemperatur i ytterligere 3 dager. Oksydasjonen av-brytes, reaksjonsblandingen helles i 3 liter isvann, innstilles på pH 9 med konsentrert ammoniakk og ekstraheres 3 ganger med kloroform. De samlede ekstrakter tørres og inndampes i vakuum. Råproduktet inneholder ifølge tynnskiktkromatografisk sammen-ligning ca. 3% utgangsmateriale, 4% sulfon og 2% andre, ukjente forurensninger. A solution of 135.6 g (0.5 mol) 2-(2-methoxy-4-methyl-mercapto-phenyl)-1H-imidazo[4,5-b]pyridine in 600 ml of 80% acetic acid is added to 57 g 30% hydrogen peroxide and allowed to stand for 2 days at laboratory temperature. After adding a further 5 g of 30% hydrogen peroxide, the reaction mixture is allowed to stand at laboratory temperature for a further 3 days. The oxidation is interrupted, the reaction mixture is poured into 3 liters of ice water, adjusted to pH 9 with concentrated ammonia and extracted 3 times with chloroform. The combined extracts are dried and evaporated in vacuo. According to thin-layer chromatographic comparison, the raw product contains approx. 3% starting material, 4% sulfone and 2% other, unknown impurities.
Ved rensning over 4000 g silikagel (elueringsmiddel: kloroform + 3% aceton) får man efter omfelling fra aceton 72,2 g (50,3% av det teoretiske) av detønskede produkt med smeltepunkt 19 8-199°C. Produktet inneholder ifølge tynnskikt-kromatogram (silikagel-ferdigplater 60 F 254 fra firma E. Merck, Darmstadt; system: kloroform/etanol (85/15)) 0,1% sulfid, 0,5% sulfon og 0,85% ukjente forbindelser som forurensninger. Eksempel 1 2-( 2- metoksy- 4- metylsulfinyl- fenyl)- lH- imidazo[ 4, 5- b] pyridin Til en suspensjon av 229,8 g 2-(2-metoksy-4-metylmerkapto-fenyl)-1H-imidazo[4,5-b]pyridin x 0,5 CH^OH og 72,1 g natriumacetat i 1,5 1 iseddik settes dråpevis under kraftig omrøring 41,1 ml brom, oppløst i 150 ml iseddik, ved en temperatur mellom . 20 og 25°C. Derefter helles reaksjonsblandingen på ca. 1 kg is og innstilles på pH 9 med konsentrert ammoniakk ved ca. 25°C. Den vandige fase ekstraheres 3 ganger med i alt 3 liter kloroform. Efter tørring av den organiske fase med magnesiumsulfat og behandling med aktivt kull fjernes oppløsningsmidlet bortsett fra en rest på 200 g, og den begynnende krystallisasjon for-hindres ved tilsetning av 40 ml metanol og oppvarmning til ca. 40-45°C. Produktet som utfelles med 1,2 1 aceton, avsuges, opp-løses i en blanding av 300 ml av hver av metanol og metylen-klorid ved 40°C, og efter inndampning i vakuum til en oppløs-ningsmiddel-rest på ca. 150 g, foretas ny utfelning med 1 liter aceton. Produktet avsuges og eftervaskes med en blanding av 200 ml aceton og 300 ml n-heksan. Purification over 4000 g of silica gel (eluent: chloroform + 3% acetone) gives, after precipitation from acetone, 72.2 g (50.3% of the theoretical) of the desired product with a melting point of 198-199°C. According to the thin-layer chromatogram (silica gel ready plates 60 F 254 from the company E. Merck, Darmstadt; system: chloroform/ethanol (85/15)) the product contains 0.1% sulphide, 0.5% sulphone and 0.85% unknown compounds as pollutants. Example 1 2-(2-Methoxy-4-methylsulfinyl-phenyl)-1H-imidazo[4,5-b]pyridine To a suspension of 229.8 g of 2-(2-methoxy-4-methylmercapto-phenyl)-1H -imidazo[4,5-b]pyridine x 0.5 CH^OH and 72.1 g of sodium acetate in 1.5 1 glacial acetic acid are added dropwise with vigorous stirring to 41.1 ml of bromine, dissolved in 150 ml of glacial acetic acid, at a temperature between . 20 and 25°C. The reaction mixture is then poured into approx. 1 kg of ice and adjusted to pH 9 with concentrated ammonia at approx. 25°C. The aqueous phase is extracted 3 times with a total of 3 liters of chloroform. After drying the organic phase with magnesium sulfate and treatment with activated charcoal, the solvent is removed except for a residue of 200 g, and the incipient crystallization is prevented by adding 40 ml of methanol and heating to approx. 40-45°C. The product that is precipitated with 1.2 1 acetone is filtered off, dissolved in a mixture of 300 ml each of methanol and methylene chloride at 40°C, and after evaporation in vacuum to a solvent residue of approx. 150 g, a new precipitation is carried out with 1 liter of acetone. The product is suctioned off and then washed with a mixture of 200 ml acetone and 300 ml n-hexane.
Utbytte: 175,1 g med smeltepunkt 201-202°C.Yield: 175.1 g with melting point 201-202°C.
Efter inndampning av moderluten og ved tilsetning av aceton får man ytterligere 36,3 g med smeltepunkt 200-201°C. After evaporation of the mother liquor and the addition of acetone, a further 36.3 g are obtained with a melting point of 200-201°C.
Samlet utbytte: 211,4 g (92% av det teoretiske).Total yield: 211.4 g (92% of the theoretical).
Det- således oppnådde produkt inneholder ifølge tynnskikt- kromatogram (silikagel-ferdigplater 60 F 254 fra firma E. Merck, Darmstadt; system: kloroform/etanol (85/15)) 0,05% sulfon og 0,25% ukjente forurensninger.' The product thus obtained contains, according to the thin-layer chromatogram (silica gel ready plates 60 F 254 from the company E. Merck, Darmstadt; system: chloroform/ethanol (85/15)) 0.05% sulfone and 0.25% unknown impurities.
Eksempel 2 Example 2
2-( 2- metoksy- 4- metylsulfinyl- fenyl)- lH- imidazo[ 4, 5- b] pyridin2-(2-Methoxy-4-methylsulfinyl-phenyl)-1H-imidazo[4,5-b]pyridine
Til en oppløsning av 5,4 g (0,02 mol) 2-(2-metoksy-4-metylmerkapto-fenyl)-lH-imidazo[4,5-b]pyridin i 30 ml 50%ig eddiksyre settes dråpevis i løpet av 20 minutter under omrøring ved romtemperatur en oppløsning som fremstilles som følger: Til 6 g natriumhydroksyd i 50 ml vann settes dråpevis- under om-røring og avkjøling med isvann 4,8 g 1,5 ml (0,03 mol) brom. Efter avsluttet reaksjon surgjøres med 45 ml iseddik under To a solution of 5.4 g (0.02 mol) 2-(2-methoxy-4-methylmercapto-phenyl)-1H-imidazo[4,5-b]pyridine in 30 ml of 50% acetic acid is added dropwise in the course of 20 minutes while stirring at room temperature, a solution is prepared as follows: To 6 g of sodium hydroxide in 50 ml of water, 4.8 g of 1.5 ml (0.03 mol) of bromine are added dropwise while stirring and cooling with ice water. After completion of the reaction, acidify with 45 ml of glacial acetic acid below
videre avkjøling.further cooling.
Den oppnådde reaksjonsblanding efterrøres i 5 minutter, fortynnes med 100 ml vann, innstilles på pH 8 med konsentrert ammoniakk og utristes 3 ganger med etylacetat. Derefter ekstraheres 3 ganger med kloroform, ekstrakten tørres over magnesiumsulfat, oppløsningsmidlet fjernes i vakuum, og den honning-aktige rest oppløses i 100 ml aceton. Sulfoksydet begynner straks å utkrystallisere. Det hvite produkt avsuges, eftervaskes med aceton og derefter med n-heksan og tørres. The resulting reaction mixture is stirred for 5 minutes, diluted with 100 ml of water, adjusted to pH 8 with concentrated ammonia and decanted 3 times with ethyl acetate. It is then extracted 3 times with chloroform, the extract is dried over magnesium sulfate, the solvent is removed in vacuo, and the honey-like residue is dissolved in 100 ml of acetone. The sulfoxide immediately begins to crystallize. The white product is filtered off, washed with acetone and then with n-hexane and dried.
Utbytte: 4,8 g (83,6% av det teoretiske),Yield: 4.8 g (83.6% of the theoretical),
smeltepunkt: 200-202°C.melting point: 200-202°C.
Eksempel 3Example 3
8- ( 2- metoksy- 4- metylsulfinyl- fenyl)- purin8-(2-Methoxy-4-methylsulfinyl-phenyl)-purine
Til en suspensjon av 250,2 g 8-(2-metoksy-4-metylmerkapto-fenyl)-purin-hydroklorid i 1,4 1 50%ig eddiksyre settes 142,0 g vannfritt natriumacetat, og blandingen omrøres i 20 minutter ved romtemperatur. Derefter tilsettes dråpevis ved kraftig om-røring en oppløsning av 127,9 g brom i 120 ml iseddik i løpet av en time. Temperaturen stiger derved fra 22 til 27°C. Efter avsluttet bromtilsetning efterrøres i 10 minutter, derefter innstilles reaksjonsblandingen på en pH-verdi på 7,5 med mettet kaliumkarbonatoppløsning, og blandingen omrøres ved- romtemperatur. Efter ca. en time begynner et bunnfall å utkrystallisere. Man lar det hele stå natten over, avsuger, vasker med kaldt vann og tørrer i vakuum ved 50°C. For rensning oppløses produktet 2 ganger i ca. 1 liter vann hver gang ved 50°C, behandles med aktivt kull og bringes langsomt til krystallisasjon ved 10°C. Derefter tørres ved 70°C i vakuum over fosforpentoksyd. 142.0 g of anhydrous sodium acetate is added to a suspension of 250.2 g of 8-(2-methoxy-4-methylmercapto-phenyl)-purine hydrochloride in 1.4 1 of 50% acetic acid, and the mixture is stirred for 20 minutes at room temperature . A solution of 127.9 g of bromine in 120 ml of glacial acetic acid is then added dropwise with vigorous stirring over the course of one hour. The temperature thereby rises from 22 to 27°C. After the addition of bromine is finished, stirring is continued for 10 minutes, then the reaction mixture is adjusted to a pH value of 7.5 with saturated potassium carbonate solution, and the mixture is stirred at room temperature. After approx. an hour, a precipitate begins to crystallize. The whole thing is left to stand overnight, suctioned off, washed with cold water and dried in a vacuum at 50°C. For cleaning, dissolve the product twice in approx. 1 liter of water each time at 50°C, treated with activated charcoal and brought slowly to crystallization at 10°C. It is then dried at 70°C in a vacuum over phosphorus pentoxide.
■Utbytte: 167 g (72% av det teoretiske),■Yield: 167 g (72% of the theoretical),
smeltepunkt: 236-238°C.melting point: 236-238°C.
Analogt med de ovenstående eksempler 1-3 ble følgende forbindelser fremstilt: 2-(2-metoksy-4-etylsulfinyl-fenyl)-1H-imidazo[4,5-b]pyridin-hydroklorid Analogous to the above examples 1-3, the following compounds were prepared: 2-(2-methoxy-4-ethylsulfinyl-phenyl)-1H-imidazo[4,5-b]pyridine hydrochloride
Smeltepunkt: 122-123°C Melting point: 122-123°C
2-(2-metoksy-5-metylsulfinyl-fenyl)-1H-imidazo[4,5-b]pyridin Smeltepunkt: 211-212°C 2-(2-Methoxy-5-methylsulfinyl-phenyl)-1H-imidazo[4,5-b]pyridine Melting point: 211-212°C
2-(2-etoksy-5-metylsulfinyl-fenyl)-1H-imidazo[4,5-b]pyridin Smeltepunkt: 199-200°C 2-(2-ethoxy-5-methylsulfinyl-phenyl)-1H-imidazo[4,5-b]pyridine Melting point: 199-200°C
2-(2-etoksy-4-etylsulfinyl-fenyl)-1H-imidazo[4,5-b]pyridin Smeltepunkt: 167-168°C 2-(2-ethoxy-4-ethylsulfinyl-phenyl)-1H-imidazo[4,5-b]pyridine Melting point: 167-168°C
2-(2-metoksy-4-propylsulfinyl-fenyl)-1H-imidazo[4,5-b]pyridin Smeltepunkt: 182-183°C 2-(2-Methoxy-4-propylsulfinyl-phenyl)-1H-imidazo[4,5-b]pyridine Melting point: 182-183°C
2-(2-etoksy-4-propylsulfinyl-fenyl)-1H-imidazo[4,5-b]pyridin Smeltepunkt: 182,5-183,5°C (dekomp.) 2-(2-ethoxy-4-propylsulfinyl-phenyl)-1H-imidazo[4,5-b]pyridine Melting point: 182.5-183.5°C (decomp.)
2-(2-etoksy-4-butylsulfinyl-fenyl)-1H-imidazo[4,5-b]pyridin Smeltepunkt: 187-188°C 2-(2-ethoxy-4-butylsulfinyl-phenyl)-1H-imidazo[4,5-b]pyridine Melting point: 187-188°C
2-(2-fluor-5-metylsulfinyl-fenyl)-1H-imidazo[4,5-b]pyridin Smeltepunkt: 191-192°C 2-(2-fluoro-5-methylsulfinyl-phenyl)-1H-imidazo[4,5-b]pyridine Melting point: 191-192°C
2-[2-(2-etylsulfinyl-etoksy)-4-metoksy-fenyl]-lH-imidazo-[4,5-b]pyridin 2-[2-(2-ethylsulfinyl-ethoxy)-4-methoxy-phenyl]-1H-imidazo-[4,5-b]pyridine
Smeltepunkt: 188-189°C Melting point: 188-189°C
2-[2-(2-metylsulfinyl-etoksy)-4-metoksy-fenyl]-lH-imidazo-[4,5-b]pyridin 2-[2-(2-methylsulfinyl-ethoxy)-4-methoxy-phenyl]-1H-imidazo-[4,5-b]pyridine
Smeltepunkt: 231-232°C Melting point: 231-232°C
2-[2-(3-metylsulfiny1-propoksy)-4-metoksy-fenyl]-lH-imidazo-[4,5-b]pyridin 2-[2-(3-methylsulfinyl-propoxy)-4-methoxy-phenyl]-1H-imidazo-[4,5-b]pyridine
Smeltepunkt: 133-134°C Melting point: 133-134°C
2- [2- (3-etylsulfiny1-propoksy)-4-metoksy-fenyl]-lH-imidazo-[4 ,5"-b] pyridin 2-[2-(3-ethylsulfinyl-propoxy)-4-methoxy-phenyl]-1H-imidazo-[4,5"-b]pyridine
Smeltepunkt: 127-128°C 2-[2- (2-metylsulfinyl-etoksy)-4-metylsulfinyl-fenyl]-1H-imidazo[4,5-b]pyridin Melting point: 127-128°C 2-[2-(2-methylsulfinyl-ethoxy)-4-methylsulfinyl-phenyl]-1H-imidazo[4,5-b]pyridine
Smeltepunkt: 193-194°C Melting point: 193-194°C
2-[2-(2-metylsulfinyl-etoksy)-4-metyl-fenyl]-lH-imidazo-[4,5-b]pyridin 2-[2-(2-methylsulfinyl-ethoxy)-4-methyl-phenyl]-1H-imidazo-[4,5-b]pyridine
Smeltepunkt: 191-192°C Melting point: 191-192°C
2-[2-(2-metylsulfinyl-etoksy)-4-klor-fényl]-1H-imidazo-[4,5-b]pyridin 2-[2-(2-methylsulfinyl-ethoxy)-4-chloro-phenyl]-1H-imidazo-[4,5-b]pyridine
Smeltepunkt: 221-222°C Melting point: 221-222°C
2-[2-metoksy-4-(2-metylsulfinyl-etoksy)-fenyl]-lH-imidazo-[4,5-b]pyridin 2-[2-Methoxy-4-(2-methylsulfinyl-ethoxy)-phenyl]-1H-imidazo-[4,5-b]pyridine
Smeltepunkt: 205-206°C Melting point: 205-206°C
2-[2-metoksy-4-(2-etylsulfiny1-etoksy)-fenyl]-lH-imidazo-[4,5-b]pyridin 2-[2-Methoxy-4-(2-ethylsulfinyl-ethoxy)-phenyl]-1H-imidazo-[4,5-b]pyridine
Smeltepunkt: 215-217°C Melting point: 215-217°C
2-[2-metoksy-4-(3-metylsulfiny1-propoksy)-fenyl]-1H-imidazo-[4,5-b]pyridin 2-[2-Methoxy-4-(3-methylsulfinyl-propoxy)-phenyl]-1H-imidazo-[4,5-b]pyridine
Smeltepunkt: 179-180°C Melting point: 179-180°C
2-[2-metoksy-4-(3-etylsulfinyl-propoksy)-fenyl]-lH-imidazo-[4,5-b]pyridin 2-[2-Methoxy-4-(3-ethylsulfinyl-propoxy)-phenyl]-1H-imidazo-[4,5-b]pyridine
Smeltepunkt: 166-167°C Melting point: 166-167°C
2-[2-(2-metylsulfinyl-etoksy)-5-metylmerkapto-fenyl]-lH-imidazo-[4,5-b]pyridin 2-[2-(2-methylsulfinyl-ethoxy)-5-methylmercapto-phenyl]-1H-imidazo-[4,5-b]pyridine
Smeltepunkt: 191-192°C Melting point: 191-192°C
8-(2-etoksy-4-metylsulfinyl-fenyl)-purin-hydroklorid Smeltepunkt: 220-221°C (dekomp.) 8-(2-ethoxy-4-methylsulfinyl-phenyl)-purine hydrochloride Melting point: 220-221°C (decomp.)
8- [4-metoksy-2- (2-me'tylsulf inyl-etoksy)-fenyl}-purin Smeltepunkt: 228-229°C 8-[4-methoxy-2-(2-methylsulfinyl-ethoxy)-phenyl}-purine Melting point: 228-229°C
2- [2-(2-fenylsulfinyl-etoksy)-4-metoksy-fenyl]-lH-imidazo-[4,5-b]pyridin 2-[2-(2-phenylsulfinyl-ethoxy)-4-methoxy-phenyl]-1H-imidazo-[4,5-b]pyridine
Smeltepunkt: 185-186°C Melting point: 185-186°C
2-[2-(2-benzylsulfinyl-etoksy)-4-metoksy-fenyl]-lH-imidazo-[4,5-b]pyridin 2-[2-(2-benzylsulfinyl-ethoxy)-4-methoxy-phenyl]-1H-imidazo-[4,5-b]pyridine
Smeltepunkt: 194-195°C 2-[ 2-(2-(4-klorfenylsulfinyl)-etoksy)-4-metoksy-fenyl]-lH-imidazo[4,5-b]pyridin Melting point: 194-195°C 2-[ 2-(2-(4-chlorophenylsulfinyl)-ethoxy)-4-methoxy-phenyl]-1H-imidazo[4,5-b]pyridine
Smeltepunkt: 172-173°C Melting point: 172-173°C
2-[2-(2-(4-metylfenylsulfinyl)-etoksy)-4-metoksy-fenyl]-1H-imidazo[4,5-b]pyridin 2-[2-(2-(4-methylphenylsulfinyl)-ethoxy)-4-methoxy-phenyl]-1H-imidazo[4,5-b]pyridine
Smeltepunkt: 110-122°C Melting point: 110-122°C
2-[2-(2-(4-metoksyfenylsulfinyl)-etoksy)-4-metoksy-fenyl]-1H-imidazo[4,5-b]pyridin 2-[2-(2-(4-Methoxyphenylsulfinyl)-ethoxy)-4-methoxy-phenyl]-1H-imidazo[4,5-b]pyridine
Smeltepunkt: 200-201°C Melting point: 200-201°C
2-[2- (2-(2-metoksyfenylsulfinyl)-etoksy)-4-metoksy-fenyl]-1H-imidazo[4,5-b]pyridin 2-[2-(2-(2-Methoxyphenylsulfinyl)-ethoxy)-4-methoxy-phenyl]-1H-imidazo[4,5-b]pyridine
Smeltepunkt: 131-133°C Melting point: 131-133°C
2-[2-(2-(3,4-dimetoksyfenylsulfinyl)-etoksy)-4-metoksy-fenyl]-1H-imidazo[4,5-b]pyridin 2-[2-(2-(3,4-dimethoxyphenylsulfinyl)-ethoxy)-4-methoxy-phenyl]-1H-imidazo[4,5-b]pyridine
Smeltepunkt: 157-159°C Melting point: 157-159°C
2-[2- (2-(2-metyl-4,5-dimetoksyfenylsulfinyl)-etoksy)-4-metoksy-fenyl] -1H-imidazo[4,5-b]pyridin 2-[2-(2-(2-methyl-4,5-dimethoxyphenylsulfinyl)-ethoxy)-4-methoxy-phenyl]-1H-imidazo[4,5-b]pyridine
Smeltepunkt: 172-173°C Melting point: 172-173°C
2-[2-(2- (4-nitrofenylsulfinyl)-etoksy)-4-metoksy-fenyl]-1H-imidazo[4,5-b]pyridin 2-[2-(2-(4-nitrophenylsulfinyl)-ethoxy)-4-methoxy-phenyl]-1H-imidazo[4,5-b]pyridine
Smeltepunkt: 203-204°C Melting point: 203-204°C
2-[2-(2-(2,4-dimetoksyfenylsulfinyl)-etoksy)-4-metoksy-fenyl]-lH-imidazo[4,5-b]pyridin 2-[2-(2-(2,4-dimethoxyphenylsulfinyl)-ethoxy)-4-methoxy-phenyl]-1H-imidazo[4,5-b]pyridine
Smeltepunkt: 179-180°C Melting point: 179-180°C
Claims (6)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19803044497 DE3044497A1 (en) | 1980-11-26 | 1980-11-26 | NEW METHOD FOR PRODUCING IMIDAZO (4,5-B) PYRIDINES AND PYRIMIDINES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO814012L true NO814012L (en) | 1982-05-27 |
Family
ID=6117613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO814012A NO814012L (en) | 1980-11-26 | 1981-11-25 | PROCEDURE FOR PREPARING IMIDAZO (4,5-B) -PYRIDINES AND PYRIMIDINES |
Country Status (20)
| Country | Link |
|---|---|
| JP (1) | JPS57116069A (en) |
| AT (1) | ATA444281A (en) |
| BG (1) | BG36346A3 (en) |
| CH (1) | CH648313A5 (en) |
| CS (1) | CS223849B2 (en) |
| DD (1) | DD201902A5 (en) |
| DE (1) | DE3044497A1 (en) |
| DK (1) | DK521881A (en) |
| ES (1) | ES8301983A1 (en) |
| FI (1) | FI813757A7 (en) |
| GR (1) | GR76304B (en) |
| HU (1) | HU183704B (en) |
| IT (1) | IT1142938B (en) |
| NL (1) | NL8104785A (en) |
| NO (1) | NO814012L (en) |
| PL (1) | PL233967A1 (en) |
| PT (1) | PT74035B (en) |
| RO (1) | RO83775B (en) |
| SE (1) | SE8107021L (en) |
| YU (1) | YU277181A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3217583A1 (en) * | 1982-05-11 | 1983-11-17 | Merck Patent Gmbh, 6100 Darmstadt | 2-ARYL-TETRAAZAINDENE |
| DE3324115A1 (en) * | 1983-07-05 | 1985-01-17 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW IMIDAZOLES, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
| US4515796A (en) * | 1983-09-08 | 1985-05-07 | Eli Lilly And Company | Certain naphthalenyl imidazo compounds and their pharmaceutical use |
| DE3522230A1 (en) * | 1985-06-21 | 1987-01-02 | Thomae Gmbh Dr K | NEW 2-ARYLIMIDAZOLES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS, AND METHOD FOR THE PRODUCTION THEREOF |
-
1980
- 1980-11-26 DE DE19803044497 patent/DE3044497A1/en not_active Withdrawn
-
1981
- 1981-10-16 AT AT0444281A patent/ATA444281A/en not_active Application Discontinuation
- 1981-10-22 NL NL8104785A patent/NL8104785A/en not_active Application Discontinuation
- 1981-11-18 DD DD81234957A patent/DD201902A5/en unknown
- 1981-11-23 CH CH7489/81A patent/CH648313A5/en not_active IP Right Cessation
- 1981-11-23 IT IT49754/81A patent/IT1142938B/en active
- 1981-11-24 FI FI813757A patent/FI813757A7/en not_active Application Discontinuation
- 1981-11-24 RO RO105857A patent/RO83775B/en unknown
- 1981-11-24 CS CS818628A patent/CS223849B2/en unknown
- 1981-11-24 DK DK521881A patent/DK521881A/en not_active Application Discontinuation
- 1981-11-25 BG BG054278A patent/BG36346A3/en unknown
- 1981-11-25 PT PT74035A patent/PT74035B/en unknown
- 1981-11-25 HU HU813523A patent/HU183704B/en unknown
- 1981-11-25 SE SE8107021A patent/SE8107021L/en not_active Application Discontinuation
- 1981-11-25 PL PL23396781A patent/PL233967A1/xx unknown
- 1981-11-25 YU YU02771/81A patent/YU277181A/en unknown
- 1981-11-25 ES ES507418A patent/ES8301983A1/en not_active Expired
- 1981-11-25 JP JP56189018A patent/JPS57116069A/en active Pending
- 1981-11-25 NO NO814012A patent/NO814012L/en unknown
- 1981-11-29 GR GR66606A patent/GR76304B/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IT1142938B (en) | 1986-10-15 |
| IT8149754A0 (en) | 1981-11-23 |
| RO83775B (en) | 1984-04-30 |
| PL233967A1 (en) | 1982-07-19 |
| ES507418A0 (en) | 1983-01-01 |
| FI813757L (en) | 1982-05-27 |
| RO83775A (en) | 1984-04-02 |
| ATA444281A (en) | 1985-06-15 |
| NL8104785A (en) | 1982-06-16 |
| PT74035A (en) | 1981-12-01 |
| SE8107021L (en) | 1982-05-27 |
| CH648313A5 (en) | 1985-03-15 |
| PT74035B (en) | 1983-12-07 |
| FI813757A7 (en) | 1982-05-27 |
| ES8301983A1 (en) | 1983-01-01 |
| YU277181A (en) | 1983-12-31 |
| GR76304B (en) | 1984-08-04 |
| CS223849B2 (en) | 1983-11-25 |
| DK521881A (en) | 1982-05-27 |
| DE3044497A1 (en) | 1982-06-24 |
| JPS57116069A (en) | 1982-07-19 |
| HU183704B (en) | 1984-05-28 |
| DD201902A5 (en) | 1983-08-17 |
| BG36346A3 (en) | 1984-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO120426B (en) | ||
| US5639886A (en) | One-pot process for the preparation of 3-quinolonecarboxylic acid derivatives | |
| NO141163B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE PYRIMIDINES | |
| EP1315727B1 (en) | 7-oxo pyridopyrimidines | |
| JP2753659B2 (en) | Pyrazole derivatives | |
| NO845252L (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 2-PHENYL-IMIDAZOLE DERIVATIVES | |
| NO842684L (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE IMIDAZOLE DERIVATIVES | |
| TW201728590A (en) | Preparation method and intermediate of pyrrolo[3,2-d]pyrimidine compound | |
| AU766129B2 (en) | Tricyclic phthalazine derivatives as phosphodiesterase 4 inhibitors | |
| NO814012L (en) | PROCEDURE FOR PREPARING IMIDAZO (4,5-B) -PYRIDINES AND PYRIMIDINES | |
| US20090209764A1 (en) | Process for Preparation of 4-amino-1-isobutyl-1H-Imidazo[4,5-C]-quinoline (Imiquimod) | |
| KR100654265B1 (en) | Method for preparing 4- (heteroaryl-methyl) -halogen-1 (2H) -phthalazinone | |
| CN109068653A (en) | The method for preparing 4- alkoxy -3- hydroxy-picolinic acid | |
| EP0359438B1 (en) | Pyridazinone manufacture | |
| SU906379A3 (en) | Method for preparing pyrido-(1,2-alpha) pyrimidines derivatives, their salts, or their optically active isomers | |
| US20030216415A1 (en) | Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones | |
| NO165248B (en) | ROOM WALL FOR USE IN A CONVERTER FOR TREATMENT OF CASTLE IRON MELTS. | |
| NZ272110A (en) | Process for the preparation of 2-amino-4,6-dichloropyrimidine | |
| JP2831000B2 (en) | (2-aminobenzoyl) acetic acid ester derivative | |
| WO2023114198A2 (en) | Methods for the synthesis of complement factor d inhibitors | |
| JPS62201869A (en) | Novel quinoline derivative and its production | |
| JPH05178888A (en) | Process for producing 4-amino-unsaturated-androstanedione derivative | |
| NO309094B1 (en) | Process for the preparation of (11 <beta>, 16 <beta>) -21- (3-carboxy-3-oxypropoxy) -11-hydroxy-2'-methyl-5'H-pregna-1,4-dieno [17 , 16-dioxazol-3,20-dione | |
| PL195421B1 (en) | Method of obtaining 5-[2-ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7-h-pyrazole[4,3-d]-pyrimidyn-7-one | |
| KR20010075229A (en) | 3-(hydroxymethyl)chromen-4-ones and process for preparing |